Selinexor and Backbone Treatments of Multiple Myeloma Patients
A phase 1/2 trial of Selinexor, Dexamethasone, Lenalidomide in multiple myeloma, run by Karyopharm Therapeutics Inc, now recruiting.
Overview
Selinexor and Backbone Treatments of Multiple Myeloma Patients is a phase 1/2 interventional study registered as NCT02343042 by Karyopharm Therapeutics Inc, with 300 participants planned, started 2015-10 and due to reach its primary completion in 2027-04. Interventions recorded: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac
Shares Karyopharm Therapeutics, Selinexor, Bortezomib, Dexamethasone.
- TrialA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Shares Pomalidomide, Bortezomib, Daratumumab, Dexamethasone.
- TrialA Study of Daratumumab
Shares Pomalidomide, Daratumumab, Dexamethasone, Lenalidomide.
- TrialA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul
Shares Bortezomib, Daratumumab, Dexamethasone, Lenalidomide.
- TrialA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
Shares Bortezomib, Daratumumab, Dexamethasone, Lenalidomide.
- TrialStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto
Shares Selinexor, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialPhase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Shares Pomalidomide, Bortezomib, Dexamethasone, Lenalidomide.